Xilio Therapeutics appointed Ben Harshbarger as Chief Legal Officer. The announcement is company/management-focused with no disclosed financial impact, guidance change, or clinical milestone.
Xilio Therapeutics appointed Ben Harshbarger as Chief Legal Officer. The announcement is company/management-focused with no disclosed financial impact, guidance change, or clinical milestone.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
